Clinical Trials Browser

Lymphoma, Follicular × pirtobrutinib × 90 days × Clear all

NCT06948786 2026-06-04

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Phase 2 Recruiting

Lymphoma, Follicular